Northwestern Urology holding free course on Advances in Genitourinary Robotic Reconstruction

Article

The Northwestern Medicine Department of Urology is offering an in-person course on the latest advances in genitourinary (GU) robotic reconstruction. The course is on Saturday, September 24 from 9:00 am to 4:30 pm (CT) at Northwestern University in Chicago, Illinois. The program will feature leaders in GU robotic reconstruction and will emphasize novel techniques and innovation in managing complex reconstructive challenges. There is no cost to attend. Space is limited to 35 attendees.

Register

Course Director: Ziho Lee, MD, Northwestern Medicine

Course Faculty Members:

Daniel D. Eun, MD, Temple University Lewis Katz School of Medicine at

Jill Buckley, MD, University of California, San Diego Health

Lee Zhao, MD, New York University Grossman School of Medicine

Click here to register and review the program

Related Videos
Group of doctors reading a document | Image Credit: © Flamingo Images - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Peter N. Tsambarlis, MD, answers a question during a Zoom video interview
Dr. Joshua Meeks in an interview with Urology Times
Doctor talking with patient | Image Credit: © Pcess609 - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
IND submitted for CTIM-76 in testicular and gynecologic cancers

IND submitted for CTIM-76 in testicular and gynecologic cancers

April 1st 2024
Article

Acceptance of the IND application would initiate a first-in-human phase 1 dose expansion and escalation trial of CTIM-76 in patients with testicular and gynecologic cancers.

Dr. Murphy on increasing diversity in cancer clinical trials

Dr. Murphy on increasing diversity in cancer clinical trials

February 29th 2024
Podcast

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

ALG.APV-527 shows initial promise in solid tumors, including GU cancers

ALG.APV-527 shows initial promise in solid tumors, including GU cancers

March 11th 2024
Article

Preliminary data showed that the treatment was well-tolerated, and a maximum tolerated dose had not yet been reached.

Destigmatizing Urology: Dr. Pettaway discusses penile cancer

Destigmatizing Urology: Dr. Pettaway discusses penile cancer

March 29th 2022
Podcast

“When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.

doctor and patient sitting, facing one another

Neoadjuvant chemotherapy found safe, efficacious in penile cancer

February 21st 2024
Article

Those who experienced a response with neoadjuvant chemotherapy had a median overall survival of 73.0 months, compared with 17.0 months among non-responders.

As Patients Live Longer, New Criteria Needed for Prostate Cancer Trials

As Patients Live Longer, New Criteria Needed for Prostate Cancer Trials

February 17th 2024
Article

Researchers sought to understand if a lack of cancer progression as monitored by radiography could substitute overall survival as a metric for metastatic prostate cancer clinical trials.

© 2024 MJH Life Sciences

All rights reserved.